USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
TRANSDERM, INC.
Address:
2161 DELAWARE AVE
SANTA CRUZ, CA 95060-5790
Phone:
N/A
URL:
N/A
EIN:
195399477
DUNS:
557564775
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,253,010.00 5
SBIR Phase II $5,487,953.00 2

Award List:

Pachyonychia congenita clinical trial using therapeutic siRNAs

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$312,655.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): ABSTRACT RNA interference (RNAi) has the potential to revolutionize treatment of dominant genetic disorders. Small inhibitory RNAs (siRNAs) are highly potent and selective, demonstrating remarkable single-nucleotide spe cificity. Clinical trials using siRNAs are… More

Development of topical rapamycin as a novel treatment for skin disorders

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$226,281.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): In the decade and a half since the discovery of the underlying mutations in the keratin 5 (K5) and K14 genes in the skin disorder epidermolysis bullosa simplex (EBS), there has been a plethora of additional research ide ntifying the genetic bases of many… More

In vivo imaging models for evaluating siRNA delivery to skin

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$148,215.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): RNA interference offers the potential of a novel therapeutic approach for treating skin disorders. The technology to design, screen and identify potent, selective, and stable small interfering RNAs (siRNAs) is now rela tively straightforward. The ability to… More

Development of siRNA delivery methodologies using in vivo imaging models

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,380,800.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): RNA interference offers the potential of a novel therapeutic approach for treating skin disorders. The ability to design, screen and identify potent, selective and stable small interfering RNAs (siRNAs) is now relative ly straightforward. Unfortunately,… More

Evaluation of siRNA uptake and functional activity in a human organotypic skin mo

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$340,859.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Although RNA interference offers high potential as a novel therapeutic approach for treating skin disorders, delivery concerns have hampered their progression to the clinic. The most efficient and effective way to deliv er functionally-active siRNA is through… More

Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$4,107,153.00
Agency:
HHS
Principal Investigator:
Roger L. Kaspar – 831-331-3258
Abstract:
DESCRIPTION (provided by applicant): RNA interference (RNAi) has the potential to revolutionize treatment of dominant genetic disorders. Small inhibitory RNAs (siRNAs) are highly potent and selective, demonstrating remarkable single-nucleotide specificity.Clinical trials using siRNAs are currently… More

Development of topical formulations for delivery of next generation mTOR inhibito

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$225,000.00
Agency:
HHS
Principal Investigator:
Roger L. Kaspar – 831-420-1684
Abstract:
DESCRIPTION (provided by applicant): We discovered that the inducible keratins 6a and 6b, mutations in which can result in the skin and nail disorder pachyonychia congenita (PC), contain regulatory motifs in their 5'-untranslated regions that make them susceptible to mTOR inhibitors, including… More